nodes	percent_of_prediction	percent_of_DWPC	metapath
Delavirdine—CYP3A4—bone cancer	0.702	1	CbGaD
Delavirdine—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00259	0.0574	CbGpPWpGaD
Delavirdine—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00195	0.0433	CbGpPWpGaD
Delavirdine—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00141	0.0313	CbGpPWpGaD
Delavirdine—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00122	0.0271	CbGpPWpGaD
Delavirdine—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00117	0.0259	CbGpPWpGaD
Delavirdine—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00109	0.0242	CbGpPWpGaD
Delavirdine—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00101	0.0223	CbGpPWpGaD
Delavirdine—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.001	0.0222	CbGpPWpGaD
Delavirdine—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000995	0.0221	CbGpPWpGaD
Delavirdine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000951	0.0211	CbGpPWpGaD
Delavirdine—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00095	0.0211	CbGpPWpGaD
Delavirdine—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000942	0.0209	CbGpPWpGaD
Delavirdine—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000906	0.0201	CbGpPWpGaD
Delavirdine—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00085	0.0188	CbGpPWpGaD
Delavirdine—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.00084	0.0186	CbGpPWpGaD
Delavirdine—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00071	0.0157	CbGpPWpGaD
Delavirdine—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000681	0.0151	CbGpPWpGaD
Delavirdine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000656	0.0145	CbGpPWpGaD
Delavirdine—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000655	0.0145	CbGpPWpGaD
Delavirdine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000617	0.0137	CbGpPWpGaD
Delavirdine—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000607	0.0135	CbGpPWpGaD
Delavirdine—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.00059	0.0131	CbGpPWpGaD
Delavirdine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000579	0.0128	CbGpPWpGaD
Delavirdine—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000567	0.0126	CbGpPWpGaD
Delavirdine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000538	0.0119	CbGpPWpGaD
Delavirdine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000527	0.0117	CbGpPWpGaD
Delavirdine—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000526	0.0117	CbGpPWpGaD
Delavirdine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000506	0.0112	CbGpPWpGaD
Delavirdine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00049	0.0109	CbGpPWpGaD
Delavirdine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000484	0.0107	CbGpPWpGaD
Delavirdine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00048	0.0106	CbGpPWpGaD
Delavirdine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00047	0.0104	CbGpPWpGaD
Delavirdine—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000468	0.0104	CbGpPWpGaD
Delavirdine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000466	0.0103	CbGpPWpGaD
Delavirdine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000462	0.0102	CbGpPWpGaD
Delavirdine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000459	0.0102	CbGpPWpGaD
Delavirdine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000446	0.0099	CbGpPWpGaD
Delavirdine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000432	0.00958	CbGpPWpGaD
Delavirdine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000428	0.00949	CbGpPWpGaD
Delavirdine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000427	0.00948	CbGpPWpGaD
Delavirdine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.00041	0.0091	CbGpPWpGaD
Delavirdine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000395	0.00875	CbGpPWpGaD
Delavirdine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000391	0.00867	CbGpPWpGaD
Delavirdine—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000386	0.00856	CbGpPWpGaD
Delavirdine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000366	0.00811	CbGpPWpGaD
Delavirdine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000362	0.00802	CbGpPWpGaD
Delavirdine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000355	0.00786	CbGpPWpGaD
Delavirdine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00033	0.00731	CbGpPWpGaD
Delavirdine—Pancytopenia—Epirubicin—bone cancer	0.000327	0.0013	CcSEcCtD
Delavirdine—Gastritis—Doxorubicin—bone cancer	0.000327	0.00129	CcSEcCtD
Delavirdine—Pain—Cisplatin—bone cancer	0.000326	0.00129	CcSEcCtD
Delavirdine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000326	0.00129	CcSEcCtD
Delavirdine—Muscular weakness—Doxorubicin—bone cancer	0.000326	0.00129	CcSEcCtD
Delavirdine—Neutropenia—Epirubicin—bone cancer	0.000322	0.00128	CcSEcCtD
Delavirdine—Abdominal distension—Doxorubicin—bone cancer	0.000321	0.00127	CcSEcCtD
Delavirdine—Upper respiratory tract infection—Epirubicin—bone cancer	0.00032	0.00127	CcSEcCtD
Delavirdine—Stomatitis—Methotrexate—bone cancer	0.00032	0.00127	CcSEcCtD
Delavirdine—Conjunctivitis—Methotrexate—bone cancer	0.000319	0.00126	CcSEcCtD
Delavirdine—Influenza—Doxorubicin—bone cancer	0.000319	0.00126	CcSEcCtD
Delavirdine—Dysphagia—Doxorubicin—bone cancer	0.000319	0.00126	CcSEcCtD
Delavirdine—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000317	0.00703	CbGpPWpGaD
Delavirdine—Eosinophilia—Doxorubicin—bone cancer	0.000316	0.00125	CcSEcCtD
Delavirdine—Feeling abnormal—Cisplatin—bone cancer	0.000315	0.00125	CcSEcCtD
Delavirdine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000314	0.00696	CbGpPWpGaD
Delavirdine—Weight increased—Epirubicin—bone cancer	0.000314	0.00124	CcSEcCtD
Delavirdine—Haematuria—Methotrexate—bone cancer	0.000313	0.00124	CcSEcCtD
Delavirdine—Pancreatitis—Doxorubicin—bone cancer	0.000313	0.00124	CcSEcCtD
Delavirdine—Hyperglycaemia—Epirubicin—bone cancer	0.000311	0.00123	CcSEcCtD
Delavirdine—Epistaxis—Methotrexate—bone cancer	0.00031	0.00123	CcSEcCtD
Delavirdine—Pneumonia—Epirubicin—bone cancer	0.000309	0.00122	CcSEcCtD
Delavirdine—Bronchitis—Doxorubicin—bone cancer	0.000307	0.00121	CcSEcCtD
Delavirdine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000305	0.00121	CcSEcCtD
Delavirdine—Pancytopenia—Doxorubicin—bone cancer	0.000303	0.0012	CcSEcCtD
Delavirdine—Body temperature increased—Cisplatin—bone cancer	0.000302	0.00119	CcSEcCtD
Delavirdine—Neuropathy peripheral—Epirubicin—bone cancer	0.000301	0.00119	CcSEcCtD
Delavirdine—Jaundice—Epirubicin—bone cancer	0.0003	0.00119	CcSEcCtD
Delavirdine—Stomatitis—Epirubicin—bone cancer	0.0003	0.00119	CcSEcCtD
Delavirdine—Urinary tract infection—Epirubicin—bone cancer	0.000299	0.00118	CcSEcCtD
Delavirdine—Conjunctivitis—Epirubicin—bone cancer	0.000299	0.00118	CcSEcCtD
Delavirdine—Neutropenia—Doxorubicin—bone cancer	0.000298	0.00118	CcSEcCtD
Delavirdine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000296	0.00117	CcSEcCtD
Delavirdine—Hepatitis—Methotrexate—bone cancer	0.000295	0.00117	CcSEcCtD
Delavirdine—Haematuria—Epirubicin—bone cancer	0.000293	0.00116	CcSEcCtD
Delavirdine—Pharyngitis—Methotrexate—bone cancer	0.000293	0.00116	CcSEcCtD
Delavirdine—Weight increased—Doxorubicin—bone cancer	0.00029	0.00115	CcSEcCtD
Delavirdine—Epistaxis—Epirubicin—bone cancer	0.00029	0.00115	CcSEcCtD
Delavirdine—Sinusitis—Epirubicin—bone cancer	0.000288	0.00114	CcSEcCtD
Delavirdine—Hyperglycaemia—Doxorubicin—bone cancer	0.000288	0.00114	CcSEcCtD
Delavirdine—Pneumonia—Doxorubicin—bone cancer	0.000286	0.00113	CcSEcCtD
Delavirdine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000283	0.00627	CbGpPWpGaD
Delavirdine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000282	0.00626	CbGpPWpGaD
Delavirdine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000282	0.00112	CcSEcCtD
Delavirdine—Hypersensitivity—Cisplatin—bone cancer	0.000281	0.00111	CcSEcCtD
Delavirdine—Bradycardia—Epirubicin—bone cancer	0.000281	0.00111	CcSEcCtD
Delavirdine—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000279	0.00619	CbGpPWpGaD
Delavirdine—Erythema multiforme—Methotrexate—bone cancer	0.000279	0.0011	CcSEcCtD
Delavirdine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000279	0.0011	CcSEcCtD
Delavirdine—Jaundice—Doxorubicin—bone cancer	0.000277	0.0011	CcSEcCtD
Delavirdine—Stomatitis—Doxorubicin—bone cancer	0.000277	0.0011	CcSEcCtD
Delavirdine—Rhinitis—Epirubicin—bone cancer	0.000277	0.0011	CcSEcCtD
Delavirdine—Conjunctivitis—Doxorubicin—bone cancer	0.000276	0.00109	CcSEcCtD
Delavirdine—Urinary tract infection—Doxorubicin—bone cancer	0.000276	0.00109	CcSEcCtD
Delavirdine—Hepatitis—Epirubicin—bone cancer	0.000276	0.00109	CcSEcCtD
Delavirdine—Tinnitus—Methotrexate—bone cancer	0.000275	0.00109	CcSEcCtD
Delavirdine—Hypoaesthesia—Epirubicin—bone cancer	0.000275	0.00109	CcSEcCtD
Delavirdine—Asthenia—Cisplatin—bone cancer	0.000274	0.00108	CcSEcCtD
Delavirdine—Pharyngitis—Epirubicin—bone cancer	0.000274	0.00108	CcSEcCtD
Delavirdine—Oedema peripheral—Epirubicin—bone cancer	0.000272	0.00108	CcSEcCtD
Delavirdine—Haematuria—Doxorubicin—bone cancer	0.000271	0.00107	CcSEcCtD
Delavirdine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000268	0.00595	CbGpPWpGaD
Delavirdine—Epistaxis—Doxorubicin—bone cancer	0.000268	0.00106	CcSEcCtD
Delavirdine—Sinusitis—Doxorubicin—bone cancer	0.000267	0.00106	CcSEcCtD
Delavirdine—Chills—Methotrexate—bone cancer	0.000265	0.00105	CcSEcCtD
Delavirdine—Diarrhoea—Cisplatin—bone cancer	0.000261	0.00103	CcSEcCtD
Delavirdine—Erythema multiforme—Epirubicin—bone cancer	0.000261	0.00103	CcSEcCtD
Delavirdine—Alopecia—Methotrexate—bone cancer	0.000261	0.00103	CcSEcCtD
Delavirdine—Bradycardia—Doxorubicin—bone cancer	0.00026	0.00103	CcSEcCtD
Delavirdine—Tinnitus—Epirubicin—bone cancer	0.000257	0.00102	CcSEcCtD
Delavirdine—Erythema—Methotrexate—bone cancer	0.000257	0.00102	CcSEcCtD
Delavirdine—Malnutrition—Methotrexate—bone cancer	0.000257	0.00102	CcSEcCtD
Delavirdine—Rhinitis—Doxorubicin—bone cancer	0.000256	0.00101	CcSEcCtD
Delavirdine—Hepatitis—Doxorubicin—bone cancer	0.000255	0.00101	CcSEcCtD
Delavirdine—Hypoaesthesia—Doxorubicin—bone cancer	0.000254	0.00101	CcSEcCtD
Delavirdine—Pharyngitis—Doxorubicin—bone cancer	0.000253	0.001	CcSEcCtD
Delavirdine—Oedema peripheral—Doxorubicin—bone cancer	0.000252	0.000996	CcSEcCtD
Delavirdine—Dysgeusia—Methotrexate—bone cancer	0.000251	0.000995	CcSEcCtD
Delavirdine—Back pain—Methotrexate—bone cancer	0.000248	0.000983	CcSEcCtD
Delavirdine—Chills—Epirubicin—bone cancer	0.000248	0.00098	CcSEcCtD
Delavirdine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000245	0.00543	CbGpPWpGaD
Delavirdine—Alopecia—Epirubicin—bone cancer	0.000244	0.000965	CcSEcCtD
Delavirdine—Vomiting—Cisplatin—bone cancer	0.000243	0.000961	CcSEcCtD
Delavirdine—Vision blurred—Methotrexate—bone cancer	0.000242	0.000958	CcSEcCtD
Delavirdine—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000242	0.00536	CbGpPWpGaD
Delavirdine—Erythema multiforme—Doxorubicin—bone cancer	0.000241	0.000956	CcSEcCtD
Delavirdine—Rash—Cisplatin—bone cancer	0.000241	0.000953	CcSEcCtD
Delavirdine—Dermatitis—Cisplatin—bone cancer	0.00024	0.000952	CcSEcCtD
Delavirdine—Erythema—Epirubicin—bone cancer	0.00024	0.000951	CcSEcCtD
Delavirdine—Malnutrition—Epirubicin—bone cancer	0.00024	0.000951	CcSEcCtD
Delavirdine—Ill-defined disorder—Methotrexate—bone cancer	0.000238	0.000943	CcSEcCtD
Delavirdine—Tinnitus—Doxorubicin—bone cancer	0.000238	0.000942	CcSEcCtD
Delavirdine—Anaemia—Methotrexate—bone cancer	0.000237	0.000939	CcSEcCtD
Delavirdine—Flatulence—Epirubicin—bone cancer	0.000237	0.000937	CcSEcCtD
Delavirdine—Tension—Epirubicin—bone cancer	0.000236	0.000933	CcSEcCtD
Delavirdine—Dysgeusia—Epirubicin—bone cancer	0.000235	0.000931	CcSEcCtD
Delavirdine—Nervousness—Epirubicin—bone cancer	0.000233	0.000924	CcSEcCtD
Delavirdine—Back pain—Epirubicin—bone cancer	0.000232	0.00092	CcSEcCtD
Delavirdine—Malaise—Methotrexate—bone cancer	0.000231	0.000916	CcSEcCtD
Delavirdine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000231	0.00513	CbGpPWpGaD
Delavirdine—Muscle spasms—Epirubicin—bone cancer	0.000231	0.000914	CcSEcCtD
Delavirdine—Vertigo—Methotrexate—bone cancer	0.000231	0.000913	CcSEcCtD
Delavirdine—Leukopenia—Methotrexate—bone cancer	0.00023	0.00091	CcSEcCtD
Delavirdine—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000229	0.00508	CbGpPWpGaD
Delavirdine—Chills—Doxorubicin—bone cancer	0.000229	0.000907	CcSEcCtD
Delavirdine—Nausea—Cisplatin—bone cancer	0.000227	0.000898	CcSEcCtD
Delavirdine—Vision blurred—Epirubicin—bone cancer	0.000226	0.000896	CcSEcCtD
Delavirdine—Alopecia—Doxorubicin—bone cancer	0.000226	0.000893	CcSEcCtD
Delavirdine—Cough—Methotrexate—bone cancer	0.000224	0.000887	CcSEcCtD
Delavirdine—Ill-defined disorder—Epirubicin—bone cancer	0.000223	0.000882	CcSEcCtD
Delavirdine—Malnutrition—Doxorubicin—bone cancer	0.000222	0.00088	CcSEcCtD
Delavirdine—Erythema—Doxorubicin—bone cancer	0.000222	0.00088	CcSEcCtD
Delavirdine—Anaemia—Epirubicin—bone cancer	0.000222	0.000879	CcSEcCtD
Delavirdine—Agitation—Epirubicin—bone cancer	0.000221	0.000874	CcSEcCtD
Delavirdine—Flatulence—Doxorubicin—bone cancer	0.000219	0.000867	CcSEcCtD
Delavirdine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000219	0.00485	CbGpPWpGaD
Delavirdine—Arthralgia—Methotrexate—bone cancer	0.000219	0.000865	CcSEcCtD
Delavirdine—Myalgia—Methotrexate—bone cancer	0.000219	0.000865	CcSEcCtD
Delavirdine—Chest pain—Methotrexate—bone cancer	0.000219	0.000865	CcSEcCtD
Delavirdine—Tension—Doxorubicin—bone cancer	0.000218	0.000863	CcSEcCtD
Delavirdine—Dysgeusia—Doxorubicin—bone cancer	0.000218	0.000862	CcSEcCtD
Delavirdine—Malaise—Epirubicin—bone cancer	0.000217	0.000857	CcSEcCtD
Delavirdine—Discomfort—Methotrexate—bone cancer	0.000216	0.000855	CcSEcCtD
Delavirdine—Nervousness—Doxorubicin—bone cancer	0.000216	0.000855	CcSEcCtD
Delavirdine—Vertigo—Epirubicin—bone cancer	0.000216	0.000854	CcSEcCtD
Delavirdine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000216	0.00478	CbGpPWpGaD
Delavirdine—Syncope—Epirubicin—bone cancer	0.000215	0.000853	CcSEcCtD
Delavirdine—Leukopenia—Epirubicin—bone cancer	0.000215	0.000851	CcSEcCtD
Delavirdine—Back pain—Doxorubicin—bone cancer	0.000215	0.000851	CcSEcCtD
Delavirdine—Muscle spasms—Doxorubicin—bone cancer	0.000214	0.000846	CcSEcCtD
Delavirdine—Palpitations—Epirubicin—bone cancer	0.000212	0.00084	CcSEcCtD
Delavirdine—Confusional state—Methotrexate—bone cancer	0.000211	0.000836	CcSEcCtD
Delavirdine—Loss of consciousness—Epirubicin—bone cancer	0.000211	0.000836	CcSEcCtD
Delavirdine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000211	0.00467	CbGpPWpGaD
Delavirdine—Cough—Epirubicin—bone cancer	0.00021	0.00083	CcSEcCtD
Delavirdine—Vision blurred—Doxorubicin—bone cancer	0.000209	0.000829	CcSEcCtD
Delavirdine—Infection—Methotrexate—bone cancer	0.000208	0.000824	CcSEcCtD
Delavirdine—Hypertension—Epirubicin—bone cancer	0.000207	0.000821	CcSEcCtD
Delavirdine—Ill-defined disorder—Doxorubicin—bone cancer	0.000206	0.000816	CcSEcCtD
Delavirdine—Anaemia—Doxorubicin—bone cancer	0.000205	0.000813	CcSEcCtD
Delavirdine—Thrombocytopenia—Methotrexate—bone cancer	0.000205	0.000812	CcSEcCtD
Delavirdine—Chest pain—Epirubicin—bone cancer	0.000205	0.00081	CcSEcCtD
Delavirdine—Arthralgia—Epirubicin—bone cancer	0.000205	0.00081	CcSEcCtD
Delavirdine—Myalgia—Epirubicin—bone cancer	0.000205	0.00081	CcSEcCtD
Delavirdine—Agitation—Doxorubicin—bone cancer	0.000204	0.000809	CcSEcCtD
Delavirdine—Anxiety—Epirubicin—bone cancer	0.000204	0.000807	CcSEcCtD
Delavirdine—Skin disorder—Methotrexate—bone cancer	0.000203	0.000805	CcSEcCtD
Delavirdine—Hyperhidrosis—Methotrexate—bone cancer	0.000203	0.000802	CcSEcCtD
Delavirdine—Discomfort—Epirubicin—bone cancer	0.000202	0.0008	CcSEcCtD
Delavirdine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000201	0.00446	CbGpPWpGaD
Delavirdine—Malaise—Doxorubicin—bone cancer	0.0002	0.000793	CcSEcCtD
Delavirdine—Dry mouth—Epirubicin—bone cancer	0.0002	0.000792	CcSEcCtD
Delavirdine—Vertigo—Doxorubicin—bone cancer	0.0002	0.00079	CcSEcCtD
Delavirdine—Anorexia—Methotrexate—bone cancer	0.0002	0.00079	CcSEcCtD
Delavirdine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000199	0.00442	CbGpPWpGaD
Delavirdine—Syncope—Doxorubicin—bone cancer	0.000199	0.000789	CcSEcCtD
Delavirdine—Leukopenia—Doxorubicin—bone cancer	0.000199	0.000788	CcSEcCtD
Delavirdine—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000199	0.0044	CbGpPWpGaD
Delavirdine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000198	0.0044	CbGpPWpGaD
Delavirdine—Confusional state—Epirubicin—bone cancer	0.000198	0.000782	CcSEcCtD
Delavirdine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000197	0.00436	CbGpPWpGaD
Delavirdine—Palpitations—Doxorubicin—bone cancer	0.000196	0.000778	CcSEcCtD
Delavirdine—Oedema—Epirubicin—bone cancer	0.000196	0.000776	CcSEcCtD
Delavirdine—Hypotension—Methotrexate—bone cancer	0.000196	0.000775	CcSEcCtD
Delavirdine—Loss of consciousness—Doxorubicin—bone cancer	0.000195	0.000773	CcSEcCtD
Delavirdine—Infection—Epirubicin—bone cancer	0.000195	0.000771	CcSEcCtD
Delavirdine—Cough—Doxorubicin—bone cancer	0.000194	0.000768	CcSEcCtD
Delavirdine—Shock—Epirubicin—bone cancer	0.000193	0.000763	CcSEcCtD
Delavirdine—Thrombocytopenia—Epirubicin—bone cancer	0.000192	0.00076	CcSEcCtD
Delavirdine—Hypertension—Doxorubicin—bone cancer	0.000192	0.00076	CcSEcCtD
Delavirdine—Tachycardia—Epirubicin—bone cancer	0.000191	0.000757	CcSEcCtD
Delavirdine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000191	0.000756	CcSEcCtD
Delavirdine—Skin disorder—Epirubicin—bone cancer	0.00019	0.000754	CcSEcCtD
Delavirdine—Hyperhidrosis—Epirubicin—bone cancer	0.00019	0.00075	CcSEcCtD
Delavirdine—Insomnia—Methotrexate—bone cancer	0.000189	0.00075	CcSEcCtD
Delavirdine—Arthralgia—Doxorubicin—bone cancer	0.000189	0.000749	CcSEcCtD
Delavirdine—Chest pain—Doxorubicin—bone cancer	0.000189	0.000749	CcSEcCtD
Delavirdine—Myalgia—Doxorubicin—bone cancer	0.000189	0.000749	CcSEcCtD
Delavirdine—Anxiety—Doxorubicin—bone cancer	0.000189	0.000746	CcSEcCtD
Delavirdine—Paraesthesia—Methotrexate—bone cancer	0.000188	0.000745	CcSEcCtD
Delavirdine—Discomfort—Doxorubicin—bone cancer	0.000187	0.00074	CcSEcCtD
Delavirdine—Anorexia—Epirubicin—bone cancer	0.000187	0.00074	CcSEcCtD
Delavirdine—Dyspnoea—Methotrexate—bone cancer	0.000187	0.000739	CcSEcCtD
Delavirdine—Somnolence—Methotrexate—bone cancer	0.000186	0.000737	CcSEcCtD
Delavirdine—Dry mouth—Doxorubicin—bone cancer	0.000185	0.000733	CcSEcCtD
Delavirdine—Dyspepsia—Methotrexate—bone cancer	0.000184	0.00073	CcSEcCtD
Delavirdine—Hypotension—Epirubicin—bone cancer	0.000183	0.000725	CcSEcCtD
Delavirdine—Confusional state—Doxorubicin—bone cancer	0.000183	0.000724	CcSEcCtD
Delavirdine—Decreased appetite—Methotrexate—bone cancer	0.000182	0.000721	CcSEcCtD
Delavirdine—Oedema—Doxorubicin—bone cancer	0.000181	0.000718	CcSEcCtD
Delavirdine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000181	0.000716	CcSEcCtD
Delavirdine—Fatigue—Methotrexate—bone cancer	0.000181	0.000715	CcSEcCtD
Delavirdine—Infection—Doxorubicin—bone cancer	0.00018	0.000713	CcSEcCtD
Delavirdine—Pain—Methotrexate—bone cancer	0.000179	0.000709	CcSEcCtD
Delavirdine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000179	0.000707	CcSEcCtD
Delavirdine—Shock—Doxorubicin—bone cancer	0.000178	0.000706	CcSEcCtD
Delavirdine—Thrombocytopenia—Doxorubicin—bone cancer	0.000178	0.000703	CcSEcCtD
Delavirdine—Insomnia—Epirubicin—bone cancer	0.000177	0.000702	CcSEcCtD
Delavirdine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000177	0.00393	CbGpPWpGaD
Delavirdine—Tachycardia—Doxorubicin—bone cancer	0.000177	0.000701	CcSEcCtD
Delavirdine—Skin disorder—Doxorubicin—bone cancer	0.000176	0.000697	CcSEcCtD
Delavirdine—Paraesthesia—Epirubicin—bone cancer	0.000176	0.000697	CcSEcCtD
Delavirdine—Hyperhidrosis—Doxorubicin—bone cancer	0.000175	0.000694	CcSEcCtD
Delavirdine—Dyspnoea—Epirubicin—bone cancer	0.000175	0.000692	CcSEcCtD
Delavirdine—Somnolence—Epirubicin—bone cancer	0.000174	0.00069	CcSEcCtD
Delavirdine—Anorexia—Doxorubicin—bone cancer	0.000173	0.000684	CcSEcCtD
Delavirdine—Feeling abnormal—Methotrexate—bone cancer	0.000173	0.000683	CcSEcCtD
Delavirdine—Dyspepsia—Epirubicin—bone cancer	0.000173	0.000683	CcSEcCtD
Delavirdine—Gastrointestinal pain—Methotrexate—bone cancer	0.000171	0.000678	CcSEcCtD
Delavirdine—Decreased appetite—Epirubicin—bone cancer	0.00017	0.000675	CcSEcCtD
Delavirdine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00017	0.00378	CbGpPWpGaD
Delavirdine—Hypotension—Doxorubicin—bone cancer	0.00017	0.000671	CcSEcCtD
Delavirdine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000169	0.00067	CcSEcCtD
Delavirdine—Fatigue—Epirubicin—bone cancer	0.000169	0.000669	CcSEcCtD
Delavirdine—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000168	0.00374	CbGpPWpGaD
Delavirdine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000168	0.00373	CbGpPWpGaD
Delavirdine—Constipation—Epirubicin—bone cancer	0.000168	0.000664	CcSEcCtD
Delavirdine—Pain—Epirubicin—bone cancer	0.000168	0.000664	CcSEcCtD
Delavirdine—Urticaria—Methotrexate—bone cancer	0.000166	0.000659	CcSEcCtD
Delavirdine—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000166	0.00368	CbGpPWpGaD
Delavirdine—Body temperature increased—Methotrexate—bone cancer	0.000166	0.000656	CcSEcCtD
Delavirdine—Abdominal pain—Methotrexate—bone cancer	0.000166	0.000656	CcSEcCtD
Delavirdine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000165	0.000654	CcSEcCtD
Delavirdine—Insomnia—Doxorubicin—bone cancer	0.000164	0.000649	CcSEcCtD
Delavirdine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000163	0.00361	CbGpPWpGaD
Delavirdine—Paraesthesia—Doxorubicin—bone cancer	0.000163	0.000645	CcSEcCtD
Delavirdine—Dyspnoea—Doxorubicin—bone cancer	0.000162	0.00064	CcSEcCtD
Delavirdine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000162	0.00358	CbGpPWpGaD
Delavirdine—Feeling abnormal—Epirubicin—bone cancer	0.000162	0.00064	CcSEcCtD
Delavirdine—Somnolence—Doxorubicin—bone cancer	0.000161	0.000638	CcSEcCtD
Delavirdine—Gastrointestinal pain—Epirubicin—bone cancer	0.00016	0.000635	CcSEcCtD
Delavirdine—Dyspepsia—Doxorubicin—bone cancer	0.00016	0.000632	CcSEcCtD
Delavirdine—Decreased appetite—Doxorubicin—bone cancer	0.000158	0.000624	CcSEcCtD
Delavirdine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000157	0.00062	CcSEcCtD
Delavirdine—Fatigue—Doxorubicin—bone cancer	0.000156	0.000619	CcSEcCtD
Delavirdine—Urticaria—Epirubicin—bone cancer	0.000156	0.000617	CcSEcCtD
Delavirdine—Pain—Doxorubicin—bone cancer	0.000155	0.000614	CcSEcCtD
Delavirdine—Constipation—Doxorubicin—bone cancer	0.000155	0.000614	CcSEcCtD
Delavirdine—Body temperature increased—Epirubicin—bone cancer	0.000155	0.000613	CcSEcCtD
Delavirdine—Abdominal pain—Epirubicin—bone cancer	0.000155	0.000613	CcSEcCtD
Delavirdine—Hypersensitivity—Methotrexate—bone cancer	0.000154	0.000611	CcSEcCtD
Delavirdine—Asthenia—Methotrexate—bone cancer	0.00015	0.000595	CcSEcCtD
Delavirdine—Feeling abnormal—Doxorubicin—bone cancer	0.000149	0.000592	CcSEcCtD
Delavirdine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000148	0.000587	CcSEcCtD
Delavirdine—Pruritus—Methotrexate—bone cancer	0.000148	0.000587	CcSEcCtD
Delavirdine—Hypersensitivity—Epirubicin—bone cancer	0.000144	0.000572	CcSEcCtD
Delavirdine—Urticaria—Doxorubicin—bone cancer	0.000144	0.00057	CcSEcCtD
Delavirdine—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000144	0.00319	CbGpPWpGaD
Delavirdine—Abdominal pain—Doxorubicin—bone cancer	0.000143	0.000568	CcSEcCtD
Delavirdine—Body temperature increased—Doxorubicin—bone cancer	0.000143	0.000568	CcSEcCtD
Delavirdine—Diarrhoea—Methotrexate—bone cancer	0.000143	0.000567	CcSEcCtD
Delavirdine—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000142	0.00315	CbGpPWpGaD
Delavirdine—Asthenia—Epirubicin—bone cancer	0.000141	0.000557	CcSEcCtD
Delavirdine—Pruritus—Epirubicin—bone cancer	0.000139	0.000549	CcSEcCtD
Delavirdine—Dizziness—Methotrexate—bone cancer	0.000139	0.000548	CcSEcCtD
Delavirdine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000138	0.00306	CbGpPWpGaD
Delavirdine—Diarrhoea—Epirubicin—bone cancer	0.000134	0.000531	CcSEcCtD
Delavirdine—Hypersensitivity—Doxorubicin—bone cancer	0.000134	0.000529	CcSEcCtD
Delavirdine—Vomiting—Methotrexate—bone cancer	0.000133	0.000527	CcSEcCtD
Delavirdine—Rash—Methotrexate—bone cancer	0.000132	0.000523	CcSEcCtD
Delavirdine—Dermatitis—Methotrexate—bone cancer	0.000132	0.000522	CcSEcCtD
Delavirdine—Headache—Methotrexate—bone cancer	0.000131	0.000519	CcSEcCtD
Delavirdine—Asthenia—Doxorubicin—bone cancer	0.00013	0.000515	CcSEcCtD
Delavirdine—Dizziness—Epirubicin—bone cancer	0.00013	0.000513	CcSEcCtD
Delavirdine—Pruritus—Doxorubicin—bone cancer	0.000128	0.000508	CcSEcCtD
Delavirdine—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000126	0.00278	CbGpPWpGaD
Delavirdine—Vomiting—Epirubicin—bone cancer	0.000125	0.000493	CcSEcCtD
Delavirdine—Nausea—Methotrexate—bone cancer	0.000124	0.000493	CcSEcCtD
Delavirdine—Diarrhoea—Doxorubicin—bone cancer	0.000124	0.000491	CcSEcCtD
Delavirdine—Rash—Epirubicin—bone cancer	0.000124	0.000489	CcSEcCtD
Delavirdine—Dermatitis—Epirubicin—bone cancer	0.000123	0.000489	CcSEcCtD
Delavirdine—Headache—Epirubicin—bone cancer	0.000123	0.000486	CcSEcCtD
Delavirdine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000122	0.0027	CbGpPWpGaD
Delavirdine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.00012	0.00266	CbGpPWpGaD
Delavirdine—Dizziness—Doxorubicin—bone cancer	0.00012	0.000475	CcSEcCtD
Delavirdine—Nausea—Epirubicin—bone cancer	0.000116	0.000461	CcSEcCtD
Delavirdine—Vomiting—Doxorubicin—bone cancer	0.000115	0.000457	CcSEcCtD
Delavirdine—Rash—Doxorubicin—bone cancer	0.000114	0.000453	CcSEcCtD
Delavirdine—Dermatitis—Doxorubicin—bone cancer	0.000114	0.000452	CcSEcCtD
Delavirdine—Headache—Doxorubicin—bone cancer	0.000114	0.00045	CcSEcCtD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000114	0.00252	CbGpPWpGaD
Delavirdine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000112	0.00249	CbGpPWpGaD
Delavirdine—Nausea—Doxorubicin—bone cancer	0.000108	0.000427	CcSEcCtD
Delavirdine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000107	0.00238	CbGpPWpGaD
Delavirdine—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000105	0.00234	CbGpPWpGaD
Delavirdine—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000104	0.00231	CbGpPWpGaD
Delavirdine—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000104	0.00231	CbGpPWpGaD
Delavirdine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000103	0.00228	CbGpPWpGaD
Delavirdine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000102	0.00227	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000101	0.00224	CbGpPWpGaD
Delavirdine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	9.69e-05	0.00215	CbGpPWpGaD
Delavirdine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	9.42e-05	0.00209	CbGpPWpGaD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	9.34e-05	0.00207	CbGpPWpGaD
Delavirdine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	9.29e-05	0.00206	CbGpPWpGaD
Delavirdine—CYP2C8—Biological oxidations—GSTP1—bone cancer	9.02e-05	0.002	CbGpPWpGaD
Delavirdine—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	8.9e-05	0.00197	CbGpPWpGaD
Delavirdine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	8.73e-05	0.00194	CbGpPWpGaD
Delavirdine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	8.66e-05	0.00192	CbGpPWpGaD
Delavirdine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	8.59e-05	0.0019	CbGpPWpGaD
Delavirdine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	8.54e-05	0.00189	CbGpPWpGaD
Delavirdine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	8.47e-05	0.00188	CbGpPWpGaD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	8.42e-05	0.00187	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—NT5C3A—bone cancer	8.37e-05	0.00186	CbGpPWpGaD
Delavirdine—CYP2C19—Biological oxidations—GSTP1—bone cancer	8.05e-05	0.00179	CbGpPWpGaD
Delavirdine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	7.94e-05	0.00176	CbGpPWpGaD
Delavirdine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.47e-05	0.00166	CbGpPWpGaD
Delavirdine—CYP2D6—Biological oxidations—GSTP1—bone cancer	7.41e-05	0.00164	CbGpPWpGaD
Delavirdine—CYP2C9—Biological oxidations—GSTP1—bone cancer	7.34e-05	0.00163	CbGpPWpGaD
Delavirdine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	7.34e-05	0.00163	CbGpPWpGaD
Delavirdine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	7.31e-05	0.00162	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—NDUFA12—bone cancer	7.3e-05	0.00162	CbGpPWpGaD
Delavirdine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	7.24e-05	0.00161	CbGpPWpGaD
Delavirdine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	7.24e-05	0.0016	CbGpPWpGaD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	6.62e-05	0.00147	CbGpPWpGaD
Delavirdine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	6.62e-05	0.00147	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—NDUFA12—bone cancer	6.32e-05	0.0014	CbGpPWpGaD
Delavirdine—CYP1A2—Biological oxidations—GSTP1—bone cancer	6.27e-05	0.00139	CbGpPWpGaD
Delavirdine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	6.19e-05	0.00137	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—NT5C3A—bone cancer	6.05e-05	0.00134	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—NDUFA12—bone cancer	5.64e-05	0.00125	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—NT5C3A—bone cancer	5.24e-05	0.00116	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—NDUFA12—bone cancer	5.19e-05	0.00115	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—NDUFA12—bone cancer	5.15e-05	0.00114	CbGpPWpGaD
Delavirdine—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.84e-05	0.00107	CbGpPWpGaD
Delavirdine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.78e-05	0.00106	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—NT5C3A—bone cancer	4.68e-05	0.00104	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—NDUFA12—bone cancer	4.4e-05	0.000975	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—NT5C3A—bone cancer	4.3e-05	0.000954	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—NT5C3A—bone cancer	4.26e-05	0.000945	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—ENO2—bone cancer	3.67e-05	0.000813	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—NT5C3A—bone cancer	3.64e-05	0.000808	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—DHFR—bone cancer	3.4e-05	0.000754	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—NDUFA12—bone cancer	3.39e-05	0.000752	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—GNA11—bone cancer	3.18e-05	0.000705	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—CYP3A4—bone cancer	2.88e-05	0.000639	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—NT5C3A—bone cancer	2.81e-05	0.000623	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—ENO2—bone cancer	2.65e-05	0.000587	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—GSTP1—bone cancer	2.46e-05	0.000546	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—DHFR—bone cancer	2.46e-05	0.000545	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—GNA11—bone cancer	2.3e-05	0.000509	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—ENO2—bone cancer	2.3e-05	0.000509	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—DHFR—bone cancer	2.13e-05	0.000472	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—CYP3A4—bone cancer	2.08e-05	0.000462	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—ENO2—bone cancer	2.05e-05	0.000454	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—GNA11—bone cancer	1.99e-05	0.000441	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—DHFR—bone cancer	1.9e-05	0.000421	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—ENO2—bone cancer	1.88e-05	0.000418	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—ENO2—bone cancer	1.87e-05	0.000414	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—CYP3A4—bone cancer	1.8e-05	0.0004	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.79e-05	0.000398	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—GSTP1—bone cancer	1.78e-05	0.000395	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—GNA11—bone cancer	1.78e-05	0.000394	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—DHFR—bone cancer	1.75e-05	0.000387	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—DHFR—bone cancer	1.73e-05	0.000384	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—GNA11—bone cancer	1.63e-05	0.000362	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—GNA11—bone cancer	1.62e-05	0.000359	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.61e-05	0.000357	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.6e-05	0.000355	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—ENO2—bone cancer	1.6e-05	0.000354	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—GSTP1—bone cancer	1.54e-05	0.000342	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.48e-05	0.000328	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—DHFR—bone cancer	1.48e-05	0.000328	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.47e-05	0.000325	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.46e-05	0.000324	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—GNA11—bone cancer	1.38e-05	0.000307	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—GSTP1—bone cancer	1.38e-05	0.000305	CbGpPWpGaD
Delavirdine—CYP3A7—Metabolism—PTGS2—bone cancer	1.28e-05	0.000283	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—GSTP1—bone cancer	1.27e-05	0.000281	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—GSTP1—bone cancer	1.26e-05	0.000278	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.25e-05	0.000278	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.25e-05	0.000277	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—ENO2—bone cancer	1.23e-05	0.000273	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—DHFR—bone cancer	1.14e-05	0.000253	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—GSTP1—bone cancer	1.07e-05	0.000238	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—GNA11—bone cancer	1.07e-05	0.000237	CbGpPWpGaD
Delavirdine—CYP3A5—Metabolism—PTGS2—bone cancer	9.23e-06	0.000205	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—GSTP1—bone cancer	8.28e-06	0.000184	CbGpPWpGaD
Delavirdine—CYP2C8—Metabolism—PTGS2—bone cancer	7.99e-06	0.000177	CbGpPWpGaD
Delavirdine—CYP2C19—Metabolism—PTGS2—bone cancer	7.13e-06	0.000158	CbGpPWpGaD
Delavirdine—CYP2D6—Metabolism—PTGS2—bone cancer	6.56e-06	0.000145	CbGpPWpGaD
Delavirdine—CYP2C9—Metabolism—PTGS2—bone cancer	6.51e-06	0.000144	CbGpPWpGaD
Delavirdine—CYP1A2—Metabolism—PTGS2—bone cancer	5.56e-06	0.000123	CbGpPWpGaD
Delavirdine—CYP3A4—Metabolism—PTGS2—bone cancer	4.29e-06	9.51e-05	CbGpPWpGaD
